Real-world Experience With Drug-coated Balloon Angioplasty in Dysfunctional Arteriovenous Fistulae

Abstract

Recent randomized trial data comparing drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (sPTA) in stenotic lesions of dysfunctional, autogenous arteriovenous fistulas has demonstrated the superiority of drug-coated devices. Strict limitations in terms of lesion type, size, length, comorbidity and location, however (as is common for randomized trials), make the results less applicable to real-world patients. The objective of this study was to evaluate the efficacy of DCB compared with sPTA for dysfunctional arteriovenous fistulae, including non-de-novo lesions and the presence of stents within the circuit.